Quantum BioPharma Advances Lucid-MS and unbuzzd in Podcast
Quantum BioPharma (QNTM) features Lucid-MS for MS and unbuzzd product in BioMedWire Podcast. Learn about Phase 2 trial plans and commercial strategy.
This news matters because Quantum BioPharma is advancing a potential treatment for multiple sclerosis, a debilitating disease affecting millions worldwide, while also generating revenue from a commercial product for alcohol metabolism. The company’s dual strategy reduces risk and provides near-term cash flow, making it an attractive opportunity for investors interested in biotech innovations.